View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 12, 2021updated 12 Jul 2022 11:18am

WCG acquires Avoca to enhance trial quality management

WCG acquires The Avoca Group to expand its portfolio of solutions to enhance clinical trial quality management

WCG has acquired life-sciences consulting firm, The Avoca Group, to expand its portfolio of solutions for enhancing clinical trial quality management and compliance transformation.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Focused on advancing efficiency, boosting process quality and alleviating risk in clinical trials, Avoca supports biopharma, biotech, CRO and clinical service providers.

The deal is expected to bolster WCG’s leadership in benchmarking and analytics of clinical trials along with the capabilities of already acquired companies, KMR Group and Metrics Champion Consortium.

This will potentially position WCG as a global leader to drive quality management best practices and compliance throughout the clinical trials industries.

WCG chairman and CEO Donald Deieso said: “Combined with the mounting pressures on the biopharmaceutical industry to increase development success rates while bringing new products to market faster, we have reached a tipping point where quality management and quality by design will assume unprecedented levels of importance to patient communities, regulators, and healthcare stakeholders.

“The Avoca Group brings exceptionally strong leadership to WCG and the respect and engagement of top-tier biopharmaceutical companies, CROs and clinical research sites in their work of establishing clinical trial best practices.”

WCG works on enhancing patient access to required treatments by cutting down the time needed, and costs incurred in conducting clinical trials, guaranteeing regulatory compliance as well as better quality management.

The Avoca Group founder and CEO Patricia Leuchten said: “Our mission aligns with the mission of WCG as a transformative and unifying force for increasing the quality and compliance of clinical trials, assuring that medicines can reach patients faster and reliably.”

With the acquisition, The Avoca Group will become WCG Avoca while continuing its management structure and its headquarters in Princeton, NJ, in the US.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena